Vylor Inc. (VYLR)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and sell at a sensible price. Vylor's description - seed and genetics, biotechnology and gene editing, founded in 1802 with 21,500 employees - suggests an entrenched agricultural franchise. In the first quarter of 2026 (2026-Q1), it reported revenue of $3.0 billion, net income of $494.0 million, and a 16.23% margin. That is real profitability, and the balance sheet looks sturdy: a D/E of 0.19 and a FairStock Altman Z-Score of 4.00. But the capital returns are poor. FairStock calculations show ROE of 4.26% and ROCE of 4.55%, not the signature of a wide moat. The data give revenue growth of 12.41% and profit growth of 24.43%, though no filing period is identified for those growth rates. Yet the price is steep. At the 2026-10-13 close of $76.94, FairStock shows a P/E of 109.91, P/B of 2.04, PEG of 4.50, and a Graham Number of $24.37, leaving a margin of safety of -215.72%. The Piotroski F-Score is 2/9 and the FairStock Score is 37/100. No Lynch category applies because there are zero years of filed results, versus the three required. A low beta of 0.58 and an Altman Z-Score of 4.00 are comforting, but price is far ahead of demonstrated earning power. I would need much better returns on capital and a longer filing record before calling this a bargain.

In plain English: Vylor is described as a seed and genetics company that uses biotechnology and gene editing. Its latest reported quarter showed $3.0 billion of revenue and $494.0 million of profit, but the shares are priced very high compared with the company's profits and accounting value. Based on the numbers given, the stock looks expensive and the overall quality signals look weak.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer